Following Richmond Pharmacology�s Chief Executive Officer and Principal Investigator Dr Jorg Taubel�s presentation at the recent 2nd DIA Cardiac Safety Workshop in Japan, further data will be presented at The 32nd Annual Meeting of The Japanese Society of Clinical Pharmacology and Therapeutics (JSCPT), taking place 1st to 3rd December 2011, at Act City Hamamatsu.This year�s annual scientific meeting will assess the latest trends in clinical pharmacology and, as a first, will be jointly hosted by the three societies of the Japanese Society of Clinical Pharmacology and Therapeutics (JPCPT), the Korean Society of Clinical Pharmacology and Therapeutics (KSCPT) and the American Society of Clinical Pharmacology and Therapeutics (ASCPT).Dr Taubel�s poster presentation session will provide an update on the original research carried out by Richmond Pharmacology, and is scheduled for Thursday, 1st December between 14:15 and 15:10:

  • Alternative Methods for the Confirmation of Assay Sensitivity in Thorough QT Studies (Program number: 1-P-77)
  • QT Prolongation in Healthy Japanese Subjects Receiving Moxifloxacin in Thorough QT Studies (Program number: 1-P-78)
  • Sex Differences of the Effect of Moxifloxacin  - A Meta -analysis of Five thorough QT Studies (Program number:  1-P-79)

Our total success rate in all Thorough QT studies reported to date confirms that we are a leading research unit for cardiac safety studies - either as a one stop solution or in conjunction with our preferred partner core labs.For further information on our cardiac safety expertise and other specialist services please speak to a company representative at booth number 5, where we will be available to discuss how Richmond can benefit your prospective Phase I/II study requirements.We look forward to seeing you in Tokyo.

Latest news

Futureproofing early phase clinical research for the next generation of investigators.

March 20, 2023
Richmond Pharmacology’s experienced Principal investigators and Co-investigators recently gave expert feedback on the ICH M11 (CeSHarP) protocol template.
Read more

Director of Operations, Keith Berelowitz, has been appointed as the Research Ethics Committee Chair for the Health Research Authority.

January 19, 2023
Keith Berelowitz will be responsible for ensuring that all ethical possibilities are explored in relation to new research.
Read more

Events

13th International Workshop on Regulatory Requirements and Current Scientific Aspects on the Preclinical and Clinical Investigation of Drug-Drug Interactions

Sunday, June 4th to Tuesday June 6th 2023
Exchange research-based knowledge on drug-drug interactions (DDIs) among all interested stakeholders from pharmaceutical industry, regulatory authorities, academic and health care delivery backgrounds and perspectives.
View event